Last reviewed · How we verify
Calcipotriene/betamethasone gel and ointment
Calcipotriene/betamethasone gel and ointment is a Topical combination therapy (vitamin D analog + corticosteroid) Small molecule drug developed by LEO Pharma. It is currently in Phase 3 development for Plaque psoriasis, Psoriatic dermatitis.
Calcipotriene (a vitamin D analog) reduces skin cell proliferation and promotes differentiation, while betamethasone (a corticosteroid) suppresses inflammation and immune response in psoriatic skin.
Calcipotriene (a vitamin D analog) reduces skin cell proliferation and promotes differentiation, while betamethasone (a corticosteroid) suppresses inflammation and immune response in psoriatic skin. Used for Plaque psoriasis, Psoriatic dermatitis.
At a glance
| Generic name | Calcipotriene/betamethasone gel and ointment |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Topical combination therapy (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR); glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriene acts as a vitamin D receptor agonist, normalizing keratinocyte differentiation and reducing hyperproliferation characteristic of psoriasis. Betamethasone dipropionate is a potent topical corticosteroid that suppresses inflammatory cytokines and immune cell infiltration. The combination provides synergistic anti-inflammatory and anti-proliferative effects on psoriatic plaques.
Approved indications
- Plaque psoriasis
- Psoriatic dermatitis
Common side effects
- Skin irritation or burning at application site
- Hypercalcemia (with systemic absorption)
- Local atrophy or striae (corticosteroid-related)
- Folliculitis
Key clinical trials
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris (PHASE3)
- LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (PHASE3)
- Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis (PHASE3)
- Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis (PHASE1)
- Nickel Desensitization Using Topical Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcipotriene/betamethasone gel and ointment CI brief — competitive landscape report
- Calcipotriene/betamethasone gel and ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about Calcipotriene/betamethasone gel and ointment
What is Calcipotriene/betamethasone gel and ointment?
How does Calcipotriene/betamethasone gel and ointment work?
What is Calcipotriene/betamethasone gel and ointment used for?
Who makes Calcipotriene/betamethasone gel and ointment?
What drug class is Calcipotriene/betamethasone gel and ointment in?
What development phase is Calcipotriene/betamethasone gel and ointment in?
What are the side effects of Calcipotriene/betamethasone gel and ointment?
What does Calcipotriene/betamethasone gel and ointment target?
Related
- Drug class: All Topical combination therapy (vitamin D analog + corticosteroid) drugs
- Target: All drugs targeting Vitamin D receptor (VDR); glucocorticoid receptor (GR)
- Manufacturer: LEO Pharma — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Plaque psoriasis
- Indication: Drugs for Psoriatic dermatitis
- Compare: Calcipotriene/betamethasone gel and ointment vs similar drugs
- Pricing: Calcipotriene/betamethasone gel and ointment cost, discount & access